moxifloxacin has been researched along with Bacterial Eye Infections in 174 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 56 (32.18) | 29.6817 |
| 2010's | 92 (52.87) | 24.3611 |
| 2020's | 26 (14.94) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, R; Barathi, VA; Beuerman, RW; Chan, LW; Jie, TY; Koh, SK; Lakshminarayanan, R; Leng, ET; Mayandi, V; Sebastian, TM; Somaraju Chalasani, ML; Ting, DSJ; Urf Turabe Fazil, MH; Varadarajan, J; Verma, NK; Xi, Q; Zhou, L | 1 |
| Cevallos, AV; Keenan, JD; Lee, MD; Lin, YB; Oji, NM; Seitzman, GD | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Das, T; Dave, VP; Joseph, J; Reddy, JC; Sharma, S; Singh, VM | 1 |
| Frings, A; Geerling, G; Goerke, P; Holtmann, C; MacKenzie, CR; Roth, M | 1 |
| Corrales, MI; Galvis, V; Garcia, D; Parra, MM; Rangel, CM; Sánchez-Ávila, R; Tello, A; Varón, CL; Villareal, E; Villarreal, D | 1 |
| Cherney, EF; Daniels, AB; Kim, SJ; Law, JC; Patel, SN; Taubenslag, KJ | 1 |
| Chang, DF; Mah, FS; Mamalis, N; Miller, KM; Myers, WG; Shorstein, NH | 1 |
| Malani, M; Nirmal, J; Saha, S; Thodikayil, AT | 1 |
| Garat, M; Lecumberri Lopez, M; Martín-Baranera, M; Moser, CL | 1 |
| Durrani, A; Jhanji, V; Kowalski, RP; Verner, A | 1 |
| Mamalis, N | 2 |
| Arshinoff, SA; Felfeli, T; Modabber, M | 1 |
| Mansoori, T; Reddy, AK; Sistla, A; Srirampur, A; Suresh, N | 1 |
| Arshinoff, SA; Modabber, M | 2 |
| Galor, A; Huang, AM; Quan, AV | 1 |
| Atta, S; Bhat, AK; Dhaliwal, D; Durrani, AF; Jhanji, V; Kowalski, RP; Mammen, A | 1 |
| Das, T; Khanna, RC; Rathi, VM; Sharma, S | 1 |
| Graue-Hernandez, EO; Lichtinger, A; Navas, A; Polania-Baron, EJ; Santana-Cruz, O | 1 |
| Austin, AF; Keenan, JD; Lalitha, P; Lietman, TM; Liu, Z; Narayana, S; Porco, TC; Prajna, NV; Radhakrishnan, N; Rajaraman, R; Rose-Nussbaumer, J | 1 |
| Ho, AC; Patel, SN; Peck, TJ | 1 |
| Bramblett, GT; Eriksson, E; Griffith, GL; Johnson, AJ; McDaniel, JS; Rebeles, J; Scott, LLF | 1 |
| Chodosh, J; Ma, KK; Saeed, HN; Tone, SO | 1 |
| Agarwal, A; Nagpal, M | 1 |
| Arshinoff, SA; Hu, A; Lukewich, MK; Modabber, M | 1 |
| Carolan, JA; Herrinton, L; Liu, L; Shorstein, NH | 1 |
| Agrawal, R; Bhatia, P; Goh, EJH; Kashikar, R; Kohli, GM; Naman, V; Sachdeva, M; Sen, A; Sen, P; Shenoy, P; Sood, D | 1 |
| Jethani, JN; Mathew, BC; Patel, A; Porwal, AC | 1 |
| Borgman, CJ | 1 |
| Libre, PE; Mathews, S | 1 |
| Grzybowski, A; Turczynowska, M | 1 |
| Tripathy, K | 1 |
| Flynn, HW; Grzybowski, A; Relhan, N; Schwartz, SG | 1 |
| Kim, JY; Lee, SJ; Nam, KY | 1 |
| Ambati, BK; Bardsley, T; Bondalapati, S; Bowen, RC; Evans, PR; Greene, T; Kliethermes, M; Lawyer, TW; Mamalis, CA; McFarland, M; Rudnisky, CJ; Shi, D; Snow, KB; Zhou, AX | 1 |
| Kim, EK; Kim, SK; Kim, TI; Ko, J; Yong, DE | 1 |
| Moussa, K; Schallhorn, JM; Shantha, J | 1 |
| Dhaliwal, DK; Kowalski, RP; Mammen, A; Romanowski, EG; Shanks, RMQ | 1 |
| Gibbons, A; Koch, DD; Leung, EH; Stout, JT | 1 |
| Chen, WL; Chu, HS; Hu, FR; Liu, HY; Wang, IJ | 1 |
| Bond, WI; Brown, JA; Hahn, JM; Kishore, K; Satar, JM | 1 |
| Chojnacki, M; Dunman, PM; Philbrick, A; Reed, JN; Tomaras, A; Wozniak, RAF; Wucher, B | 1 |
| Abdel-Meguid, AAE; Elmenofy, TMI; Gabr, AF; Nassef, MAEH; Said, MM | 1 |
| Chalam, KV; Ng, C | 1 |
| Heidary, G; Somsen, D | 1 |
| Chandrika, TN; Katta, KR; Mansoori, T; Reddy, AK; Srirampur, A | 1 |
| Chang, DF; Haripriya, A; Ravindran, RD | 2 |
| Acharya, NR; Borkar, DS; Fleiszig, SM; Ghanekar, AA; Lalitha, P; Leong, C; Li, WY; Lietman, TM; McLeod, SD; Srinivasan, M; Tam, C; Zegans, ME | 1 |
| Agarwal, P; Bansal, S; Goel, M; Sharma, N; Titiyal, JS; Upadhyaya, AD; Vajpayee, RB | 1 |
| Brown, H; Callegan, MC; Kamae, K; McEntire, MW; Mifflin, MD; Olson, RJ; Pettey, DH; Pettey, JH | 1 |
| Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A | 1 |
| Acharya, NR; Borkar, DS; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Porco, TC; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Zegans, ME | 1 |
| Ohashi, Y; Suzuki, T | 1 |
| Apsey, D; Caldwell, M; Cousineau-Krieger, C; Hensley, D; Panday, VA; Reilly, C | 1 |
| Ali, T; Callahan, C | 1 |
| Akura, J; Inoue, Y; Matsuura, K; Miyoshi, T; Suto, C | 1 |
| de la Jara, PL; Holden, BA; Naduvilath, T; Ozkan, J; Rathi, VM; Srikanth, D; Willcox, MD; Zhu, H | 1 |
| Acharya, NR; Glidden, DV; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; O'Brien, KS; Oldenburg, CE; Porco, TC; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Whitcher, JP; Zegans, ME | 1 |
| Rudnisky, CJ; Wan, D; Weis, E | 1 |
| Kawasaki, S; Mitani, A; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T | 1 |
| Acharya, NR; Keenan, JD; Lalitha, P; Lietman, TM; Mascarenhas, J; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Zegans, ME | 1 |
| Acharya, NR; Keenan, JD; Lalitha, P; Lietman, TM; Mascarenhas, J; McClintic, SM; O'Brien, KS; Oldenburg, CE; Prajna, NV; Rajaraman, R; Ray, KJ; Srinivasan, M | 1 |
| Clinch, TE; Majmudar, PA | 1 |
| Acharya, NR; Glidden, DV; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Sun, CQ; Zegans, ME | 1 |
| Farahat, HG; Mandour, SS; Marey, HM | 1 |
| Eguchi, H; Hotta, F; Kusujima, K; Kuwahara, T; Mitamura, Y; Naito, T | 1 |
| Braga-Mele, R; Chang, DF; Henderson, BA; Mamalis, N; Talley-Rostov, A; Vasavada, A | 1 |
| Bajgrowicz, M; Jones, L; Phan, CM; Subbaraman, LN | 1 |
| Baviera, J; Beltran, J; Djodeyre, MR; Llovet-Osuna, F; Llovet-Rausell, A; Ortega-Usobiaga, J | 1 |
| Akyar, I; Celik, E; Cosar, CB; Gonen, T; Ince, U; Kucuk, M; Serteser, M; Tokat, F | 1 |
| Mifflin, MD; Olson, RJ; Pettey, JH | 1 |
| Chang, DF; Haripriya, A; Namburar, S; Ravindran, RD; Smita, A | 1 |
| Fulcher, LC; Johnson, D; Jorgensen, J; Kiel, JW; McElmeel, ML; Montes, JA | 1 |
| Banta, JT; Flynn, HW; Schimel, AM; Stringham, JD | 1 |
| Bharti, SK; Kesavan, K | 1 |
| Attisano, C; Cibinel, M; Furfaro, G; Giardini, F; Grandi, G; Grignolo, FM; Machetta, F; Panepinto, G; Pollino, C; Strani, G | 1 |
| Hof, H | 1 |
| Gupta, PC; Ram, J | 1 |
| Eisen, L; Kim, J; Rosenberg, J | 1 |
| Arbisser, LB | 1 |
| Chan, I; Cockerham, G; Dhatt, HS; Egbert, PR; Fisher, E; Kaspar, HM; Montague, A; Paterno, J; Singh, K; Ta, CN | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Belani, S; Lane, SS; Masket, S; Osher, RH | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Farley, SJ; Mack, RJ; Schatz, S; Shott, S | 1 |
| Callegan, MC; Moyer, AL; Novosad, BD; Ramadan, RT; Wiskur, B | 1 |
| Berkner, L; Hazarbassanov, R; Michaeli, A; Regenbogen, M; Varssano, D; Waisbourd, M | 1 |
| Betanzos-Cabrera, G; Cancino-Díaz, JC; Cancino-Díaz, ME; González-González, G; Juárez-Verdayes, MA | 1 |
| Kobayakawa, S; Ooki, K; Tochikubo, T; Tsuji, A | 1 |
| Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Shafiee, A | 2 |
| Halachimi-Eyal, O; Halachmi-Eyal, O; Keness, Y; Lang, Y; Miron, D | 1 |
| Hori, Y; Maeda, N; Oshima, Y; Sakaguchi, H; Tominaga, A; Wakabayashi, T | 1 |
| Akyürek, N; Deren, YT; Hasanreisoğlu, B; Kalkanci, A; Ozdek, S | 1 |
| Pacheco, PA; Tam, PM | 1 |
| Balzli, CL; Caballero, AR; O'Callaghan, RJ | 1 |
| Agarwal, T; Chawla, B; Nayak, N; Satpathy, G; Shah, VM; Sharma, N; Tandon, R; Titiyal, JS; Vajpayee, RB | 1 |
| Brooks, CW; Demartelaere, SL; Johnson, AJ | 1 |
| Huang, FC; Shih, MH | 1 |
| Hesje, CK; Marquart, ME; Moore, QC; Norcross, EW; Sanders, ME; Sanfilippo, CM; Shafiee, A | 1 |
| Balzli, CL; Caballero, AR; O'Callaghan, RJ; Tang, A; Weeks, AC | 1 |
| Kim, JY; Kim, SY | 1 |
| Acharya, NR; Cevallos, V; Fintelmann, RE; Gaynor, BD; Hoskins, EN; Keenan, JD; Lietman, TM | 1 |
| Girgis, DO; Karp, CL; Miller, D | 1 |
| Alekperov, SI; Boĭko, ÉV; Fokina, DV; Reĭtuzov, VA | 1 |
| Kim, HJ; Seo, JW; Son, SW | 1 |
| Acharya, NR; Glidden, DV; Hong, KC; Lalitha, P; Lee, SM; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Zegans, ME | 2 |
| Acharya, NR; Glidden, D; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Sy, A; Zegans, ME | 1 |
| Garg, S; Milder, E; Shah, C; Vander, J | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Hooper, CY; Khan, A; Lightman, SL; Pacheco, P; Tam, PM; Taylor, SR | 1 |
| de Oliveira, LA; de Sousa, LB; do Nascimento, HM; Ecker, DJ; Magalhães, FP; Rosenblatt, MI; Sampath, R; Sannes-Lowery, KA | 1 |
| Bartell, J; Belfort, R; Bell, B; Clark, L; Gabriel, L; Höfling-Lima, AL; Martins Bispo, PJ; Muccioli, C; Stroman, DW; Zacharias Serapicos, PC | 1 |
| Acharya, NR; Lalitha, P; Lietman, TM; Mascarenhas, J; McLeod, SD; Oldenburg, CE; Priya, JL; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M; Sy, A; Zegans, ME | 1 |
| Careño, E; Herreras, JM; Portero, A; Real, LA; Villarón, S | 1 |
| Newsom, TH; Nielsen, S; Parekh, JG | 1 |
| Bosjolie, A; Qiao, M; Shih, CY; Udell, IJ | 1 |
| Herrinton, LJ; Shorstein, NH; Winthrop, KL | 1 |
| Karenchak, LM; Kowalski, RP; Kowalski, TA; Mah, FS; Romanowski, EG; Shanks, RM | 1 |
| Agarwal, T; Chawla, B; Jhanji, V; Nayak, N; Satpathy, G; Tandon, R; Titiyal, JS | 1 |
| Acharya, NR; Esterberg, EJ; Glaser, TS; Lietman, TM; McLeod, SD; Oldenburg, CE; Ray, KJ; Saravanan, S; See, CW; Srinivasan, M; Tu, EY; Zegans, ME | 1 |
| Fernandes, M; Mittal, V | 1 |
| Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M | 1 |
| Kawasaki, S; Mito, T; Ohashi, Y; Suzuki, T; Tasaka, Y; Uda, T; Uno, T | 1 |
| Acharya, NR; Geetha, M; Glidden, D; Karpagam, R; Lietman, TM; McLeod, SD; Oldenburg, CE; Prajna, L; Ray, KJ; Srinivasan, M; Sun, CQ | 1 |
| Akova, YA; Asena, L; Bozkurt, A; Demiralay, E; Goktaş, MT; Karabay, G; Yaşar, U | 1 |
| Acharya, NR; Bharathi, MJ; Glidden, DV; Lalitha, P; Lietman, TM; Manikandan, P; Mascarenhas, J; Nardone, N; Oldenburg, CE; Rajaraman, R; Ravindran, M; Ray, KJ; Srinivasan, M | 1 |
| Hwang, DG | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 2 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Herrygers, LA; Lane, LC; Levine, JM; Noecker, RJ | 1 |
| Cetinkaya, Z; Ermis, SS; Kiyici, H; Ozturk, F | 1 |
| Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H | 1 |
| Antoniadou, A; Chryssouli, Z; Giamarellou, H; Kampougeris, G; Kavouklis, E | 1 |
| Kumar, R; Marx, DP; Moshirfar, M | 1 |
| Alfonso, E; Crider, J | 1 |
| Curtis, MA; Dahlin, DC; Dembinska, O; Liao, J; Owen, GR; Robertson, SM; Rusinko, A; Schlech, BA | 1 |
| Holt, WF; Kastner, PR; McGee, DH; Rice, RL | 1 |
| Cupp, GA; Dajcs, JJ; Schlech, BA; Stroman, DW | 1 |
| Blondeau, J; Schlech, BA | 1 |
| Alfonso, E; Schlech, BA | 1 |
| Lee, SB; Mohan, SK; Oliver, KM; Slomovic, AR; Strube, YN | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Garweg, JG; Kodjikian, L | 1 |
| Feiz, V; Kang, PC; Mirzaian, G; Moshirfar, M | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Fiscella, RG; Jensen, MK | 1 |
| Asbell, PA; Bottone, EJ; Epstein, SP | 1 |
| Deramo, VA; Fastenberg, DM; Lai, JC; Udell, IJ | 1 |
| O'Brien, TP | 1 |
| Murthy, SI; Sahu, SK; Sangwan, VS; Thomas, R | 1 |
| McAllum, P; Poutanen, SM; Slomovic, AR; Srinivasan, S | 1 |
| Basavanthappa, S; Feiz, V; Moshirfar, M; Vitale, AT; Wegelin, JA; Wolsey, DH | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Flynn, HW; Harper, T; Miller, D | 1 |
| Jhanji, V; Satpathy, G; Sharma, N; Titiyal, J | 1 |
| Constantinou, M; Daniell, M; Snibson, GR; Taylor, HR; Vu, HT | 1 |
| Arshinoff, SA; Mah, FS; O'Brien, TP | 1 |
| Espandar, L; Meyer, JJ; Moshirfar, M | 1 |
| Delgado, J; Diaz, LA; Galvis, V; Gómez, AJ; Tello, A; Valencia, F | 1 |
| Amico, LM; Bucci, FA; Evans, RE | 1 |
| Acharya, NR; Chen, A; Lietman, TM; Mahalakshmi, R; McLeod, S; Prajna, L; Srinivasan, M; Whitcher, JP | 1 |
| Balzli, CL; Caballero, AR; Huang, B; McCormick, CC; O'Callaghan, RJ; Smith, E; Tang, A; Wigington, L | 1 |
| Bohigian, GM | 1 |
| Borderie, V; Bourcier, T; Dupas, B; Laroche, L; Maftouhi, AE; Puech, M; Semoun, O | 1 |
| Neiberg, MN; Sowka, J | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
17 review(s) available for moxifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
A Case of Nocardia farcinica Keratitis in a Pediatric Contact Lens Wearer.
Topics: Adolescent; Anti-Bacterial Agents; Contact Lenses, Hydrophilic; Corneal Ulcer; DNA, Bacterial; Eye Infections, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Nocardia; Nocardia Infections; RNA, Ribosomal, 16S; Visual Acuity | 2020 |
Endophthalmitis after cataract surgery: an update on recent advances.
Topics: Anti-Bacterial Agents; Cataract Extraction; Drug Implants; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Postoperative Complications; Vancomycin; Vitrectomy; Vitreous Body | 2021 |
Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Humans; Injections, Intraocular; Intraoperative Period; Moxifloxacin; Vancomycin | 2018 |
Delayed onset Mycobacterium intracellulare keratitis after laser in situ keratomileusis: A case report and literature review.
Topics: Administration, Topical; Adult; Amikacin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Keratitis; Keratomileusis, Laser In Situ; Male; Moxifloxacin; Mycobacterium avium Complex; Severity of Illness Index; Treatment Outcome | 2017 |
Bilateral Non-tuberculous Mycobacterial Keratitis After Small Incision Lenticule Extraction.
Topics: Administration, Ophthalmic; Administration, Oral; Amikacin; Anti-Bacterial Agents; Clarithromycin; Corneal Surgery, Laser; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Microsurgery; Moxifloxacin; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Myopia; Refraction, Ocular; Surgical Flaps; Tomography, Optical Coherence; Visual Acuity; Young Adult | 2018 |
Intracameral antibiotics: Safety, efficacy, and preparation.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cephalosporins; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pharmaceutical Preparations; Treatment Outcome; Vancomycin | 2014 |
Listeria infections of the eye.
Topics: Animals; Anti-Bacterial Agents; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Listeria monocytogenes; Listeriosis; Moxifloxacin | 2017 |
Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Postoperative Complications | 2016 |
Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmology; Quinolines | 2004 |
Ophthalmic infections and their anti-infective challenges.
Topics: Aza Compounds; Biological Availability; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
Topics: Administration, Topical; Animals; Aqueous Humor; Aza Compounds; Biological Availability; Cell Line; Cell Membrane Permeability; Corneal Ulcer; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines; Tears; Vitreous Body | 2005 |
Safety of moxifloxacin as shown in animal and in vitro studies.
Topics: Animals; Aza Compounds; Bacteria; Corneal Ulcer; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Ophthalmic Solutions; Quinolines; Wound Healing | 2005 |
In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone.
Topics: Administration, Topical; Animals; Aza Compounds; Bacteria; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Microbial; Eye Infections, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Topics: Aza Compounds; Eye Infections, Bacterial; Fluoroquinolones; Forecasting; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX).
Topics: Animals; Aza Compounds; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2005 |
Evidence-based review of moxifloxacin.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines; Treatment Outcome | 2006 |
Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.
Topics: Anterior Chamber; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Postoperative Complications; Quinolines | 2007 |
28 trial(s) available for moxifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
Endophthalmitis prophylaxis study. Report 1: Intracameral cefuroxime and moxifloxacin prophylaxis for the prevention of postcataract endophthalmitis in rural India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; India; Male; Middle Aged; Moxifloxacin; Postoperative Complications; Prospective Studies; Young Adult | 2020 |
Cross-Linking Assisted Infection Reduction (CLAIR): A Randomized Clinical Trial Evaluating the Effect of Adjuvant Cross-Linking on Bacterial Keratitis.
Topics: Aged; Anti-Bacterial Agents; Bacteria; Collagen; Combined Modality Therapy; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Eye Infections, Bacterial; Female; Humans; Male; Middle Aged; Moxifloxacin; Photochemotherapy; Photosensitizing Agents; Riboflavin; Treatment Outcome; Ultraviolet Rays; Visual Acuity | 2021 |
Comparative Study Between Topical Gatifloxacin 0.5% and Moxifloxacin 0.5% as a Prophylactic Measure Before Intraocular Surgery.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Corynebacterium diphtheriae; Eye Infections, Bacterial; Female; Gatifloxacin; Humans; Intraocular Pressure; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Staphylococcus aureus | 2019 |
Evaluation of moxifloxacin 0.5% in treatment of nonperforated bacterial corneal ulcers: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefazolin; Cornea; Corneal Ulcer; Drug Evaluation; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prevalence; Prospective Studies; Quinolines; Therapeutic Equivalency; Tobramycin; Treatment Outcome; Visual Acuity | 2013 |
Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.
Topics: Anti-Bacterial Agents; Aza Compounds; Communicable Diseases, Emerging; Cornea; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2013 |
Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan.
Topics: Anterior Chamber; Anti-Bacterial Agents; Aza Compounds; Cohort Studies; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Health Surveys; Humans; Injections, Intraocular; Japan; Lens Implantation, Intraocular; Moxifloxacin; Phacoemulsification; Quinolines; Retrospective Studies; Treatment Outcome | 2013 |
Effect of antibiotic drops on adverse events during extended lens wear.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Contact Lenses, Extended-Wear; Corneal Ulcer; Equipment Contamination; Eye Infections, Bacterial; Eyelids; Female; Fluoroquinolones; Gram-Positive Bacteria; Humans; Hydrogels; Male; Microbiota; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines; Silicones; Young Adult | 2014 |
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Nocardia; Nocardia Infections; Ophthalmic Solutions; Prednisolone; Quinolines; Treatment Outcome; Visual Acuity | 2014 |
Visual recovery in treated bacterial keratitis.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Quinolines; Recovery of Function; Visual Acuity | 2014 |
Visual outcomes in treated bacterial keratitis: four years of prospective follow-up.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Prospective Studies; Quinolines; Regression Analysis; Visual Acuity | 2014 |
Early addition of topical corticosteroids in the treatment of bacterial keratitis.
Topics: Administration, Topical; Adult; Aza Compounds; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Follow-Up Studies; Humans; Keratitis; Linear Models; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Prednisolone; Quinolines; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery.
Topics: Aged; Aged, 80 and over; Anterior Chamber; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Cell Count; Endophthalmitis; Endothelium, Corneal; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Intraocular Pressure; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Prospective Studies; Quinolines; Tomography, Optical Coherence; Visual Acuity | 2008 |
Preoperative topical moxifloxacin 0.5% and povidone-iodine 5.0% versus povidone-iodine 5.0% alone to reduce bacterial colonization in the conjunctival sac.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Colony Count, Microbial; Conjunctiva; Double-Blind Method; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmologic Surgical Procedures; Povidone-Iodine; Preoperative Care; Prospective Studies; Quinolines; Surgical Wound Infection; Young Adult | 2009 |
Bacterial contamination of the vitreous cavity associated with transconjunctival 25-gauge microincision vitrectomy surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Conjunctiva; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Incidence; Male; Microsurgery; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Retinal Diseases; Risk Factors; Surgical Wound Infection; Vitrectomy; Vitreous Body | 2010 |
Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacterial corneal ulcers.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefazolin; Child; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Tobramycin; Treatment Outcome; Visual Acuity; Young Adult | 2010 |
The steroids for corneal ulcers trial: study design and baseline characteristics.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Double-Blind Method; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Quinolines; Research Design; Treatment Outcome; Visual Acuity | 2012 |
Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).
Topics: Administration, Topical; Adult; Anti-Infective Agents; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Double-Blind Method; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Quinolines; Treatment Outcome; Visual Acuity | 2012 |
Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Follow-Up Studies; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Outcome; Visual Acuity | 2012 |
Safety and efficacy of moxifloxacin-dexamethasone eyedrops as treatment for bacterial ocular infection associated with bacterial blepharitis.
Topics: Administration, Ophthalmic; Adult; Anti-Infective Agents; Aza Compounds; Blepharitis; Dexamethasone; Double-Blind Method; Drug Combinations; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Quinolines | 2012 |
Nocardia keratitis: clinical course and effect of corticosteroids.
Topics: Administration, Topical; Adult; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Middle Aged; Moxifloxacin; Nocardia; Nocardia Infections; Polymerase Chain Reaction; Prednisolone; Quinolines; Treatment Outcome; Visual Acuity | 2012 |
Prior elicitation and Bayesian analysis of the Steroids for Corneal Ulcers Trial.
Topics: Administration, Topical; Anti-Infective Agents; Aza Compounds; Bayes Theorem; Corneal Ulcer; Double-Blind Method; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; Moxifloxacin; Ophthalmic Solutions; Prednisolone; Quinolines; Surveys and Questionnaires; Treatment Outcome; Visual Acuity | 2012 |
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Nocardia; Nocardia Infections; Pneumococcal Infections; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Streptococcus pneumoniae | 2013 |
Moxifloxacin susceptibility mediates the relationship between causative organism and clinical outcome in bacterial keratitis.
Topics: Administration, Topical; Anti-Infective Agents; Aza Compounds; Bacteria; Corneal Ulcer; Disease Susceptibility; Double-Blind Method; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Prednisolone; Quinolines; Treatment Outcome; Visual Acuity | 2013 |
Penetration of moxifloxacin into the human aqueous humour after oral administration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aqueous Humor; Aza Compounds; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines | 2005 |
The effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Child; Epithelium, Corneal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Male; Middle Aged; Moxifloxacin; Postoperative Care; Postoperative Complications; Prospective Studies; Quinolines; Wound Healing | 2005 |
Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Bacteria; Cefazolin; Child; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tobramycin; Treatment Outcome | 2007 |
Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Antitubercular Agents; Aqueous Humor; Aza Compounds; Conjunctiva; Dose-Response Relationship, Drug; Eye Infections, Bacterial; Eyelids; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Surgical Wound Infection; Treatment Outcome | 2008 |
Does in vitro susceptibility predict clinical outcome in bacterial keratitis?
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Corneal Ulcer; Disease Susceptibility; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pilot Projects; Prednisolone; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Visual Acuity | 2008 |
129 other study(ies) available for moxifloxacin and Bacterial Eye Infections
| Article | Year |
|---|---|
Rational Substitution of ε-Lysine for α-Lysine Enhances the Cell and Membrane Selectivity of Pore-Forming Melittin.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bees; Candida albicans; Cell Membrane; Cornea; Eye Infections, Bacterial; Female; Humans; Keratitis; Lysine; Melitten; Mice, Inbred C57BL; Microbial Sensitivity Tests; Proof of Concept Study; Rabbits; Unilamellar Liposomes | 2020 |
Assessment of Antimicrobial Activity of Dehydrated Amniotic Membrane in Infectious Keratitis: A Small Retrospective Case Series and In Vitro Study.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Adolescent; Adult; Amnion; Anti-Bacterial Agents; Eye Infections, Bacterial; Humans; Keratitis; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pneumoniae | 2021 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
Clinical features and microbiology of post-cataract surgery endophthalmitis with and without intracameral moxifloxacin prophylaxis: Endophthalmitis prophylaxis study report 3.
Topics: Adolescent; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Postoperative Complications; Retrospective Studies | 2022 |
Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019.
Topics: Anti-Bacterial Agents; Bacteria; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Gentamicins; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tertiary Care Centers | 2022 |
ENDOPHTHALMITIS IN OPHTHALMOLOGICAL REFERRAL CENTRE IN COLOMBIA: AETIOLOGY AND MICROBIAL RESISTANCE.
Topics: Adult; Anti-Bacterial Agents; Colombia; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Imipenem; Male; Moxifloxacin; Referral and Consultation; Retrospective Studies; Vancomycin | 2022 |
Intravitreal triple therapy with vancomycin, ceftazidime, and moxifloxacin for bacterial endophthalmitis: A Twelve-year experience.
Topics: Anti-Bacterial Agents; Ceftazidime; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Retrospective Studies; Vancomycin; Vitreous Body | 2023 |
ASCRS clinical advisory on intracameral moxifloxacin injection for infection prophylaxis.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Postoperative Complications | 2023 |
Carboxylated nanofibrillated cellulose empowers moxifloxacin to overcome Staphylococcus aureus biofilm in bacterial keratitis.
Topics: Anti-Bacterial Agents; Bacteria; Biofilms; Cellulose; Cornea; Eye Infections, Bacterial; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Staphylococcal Infections; Staphylococcus aureus | 2024 |
Prophylactic intracameral cefazolin and postoperative topical moxifloxacin after cataract surgery: endophthalmitis risk reduction and safety results in a 16-year study.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefazolin; Endophthalmitis; Eye Infections, Bacterial; Female; Follow-Up Studies; Forecasting; Humans; Injections, Intraocular; Male; Moxifloxacin; Phacoemulsification; Postoperative Care; Retrospective Studies; Surgical Wound Infection | 2019 |
Reducing the risk of endophthalmitis.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin; Postoperative Complications; Risk Factors; Risk Reduction Behavior | 2019 |
Aqueous level abatement profiles of intracameral antibiotics: A comparative mathematical model of moxifloxacin, cefuroxime, and vancomycin with determination of relative efficacies.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aqueous Humor; Bacteria; Cataract Extraction; Cefuroxime; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Humans; Microbial Sensitivity Tests; Models, Theoretical; Moxifloxacin; Vancomycin | 2019 |
Retrocorneal abscess: an unusual presentation of Nocardia keratitis after Descemet's stripping endothelial keratoplasty.
Topics: Abscess; Aged, 80 and over; Anti-Bacterial Agents; Antihypertensive Agents; Atropine; Corneal Diseases; Descemet Stripping Endothelial Keratoplasty; Eye Infections, Bacterial; Female; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Mydriatics; Nocardia; Nocardia Infections; Postoperative Complications; Slit Lamp Microscopy; Tomography, Optical Coherence; Visual Acuity | 2020 |
Injection volume and intracameral moxifloxacin dose.
Topics: Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin | 2020 |
Ciprofloxacin Corneal Deposits With Complete Dissipation After Switching to Moxifloxacin.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Cornea; Corneal Ulcer; Drug Substitution; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Pseudomonas Infections; Slit Lamp Microscopy | 2020 |
Methicillin-Resistant Staphylococcus aureus Keratitis: Initial Treatment, Risk Factors, Clinical Features, and Treatment Outcomes.
Topics: Administration, Ophthalmic; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefazolin; Corneal Ulcer; Drug Combinations; Eye Infections, Bacterial; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Retrospective Studies; Risk Factors; Staphylococcal Infections; Tobramycin; Treatment Outcome; Vancomycin | 2020 |
Treatment of Severe Infectious Keratitis With Scleral Contact Lenses as a Reservoir of Moxifloxacin 0.5.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aspergillosis; Contact Lenses; Corneal Ulcer; Drug Carriers; Escherichia coli Infections; Eye Infections, Bacterial; Eye Infections, Fungal; Female; Humans; Male; Middle Aged; Moxifloxacin; Prospective Studies; Pseudomonas Infections; Sclera; Staphylococcal Infections; Visual Acuity; Young Adult | 2021 |
Treatment of Corneal Infections Utilizing an Ocular Wound Chamber.
Topics: Animals; Eye Infections, Bacterial; Eye Injuries; Guinea Pigs; Keratitis; Moxifloxacin; Pseudomonas aeruginosa | 2020 |
Ochrobactrum anthropi Keratitis in a Boston Type 1 Keratoprosthesis Recipient.
Topics: Aged; Anti-Bacterial Agents; Artificial Organs; Ceftazidime; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Gram-Negative Bacterial Infections; Humans; Male; Moxifloxacin; Ochrobactrum anthropi; Prostheses and Implants; Slit Lamp Microscopy; Visual Acuity | 2021 |
Intravitreal moxifloxacin injections in acute post-cataract surgery endophthalmitis: Efficacy and safety.
Topics: Anti-Bacterial Agents; Cataract; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Humans; Intravitreal Injections; Moxifloxacin; Retrospective Studies; Vitrectomy | 2021 |
Incremental effect of topical and oral moxifloxacin administration with surgical intracameral prophylaxis.
Topics: Administration, Topical; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Quinolines | 2021 |
Endophthalmitis Prophylaxis Failures in Patients Injected With Intracameral Antibiotic During Cataract Surgery.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacteria; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Injections, Intraocular; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; Phacoemulsification; Retrospective Studies; Treatment Failure | 2021 |
Impact of prophylactic intracameral moxifloxacin on post-cataract surgery endophthalmitis: data from a tertiary eye care facility in rural India.
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Humans; India; Moxifloxacin; Postoperative Complications; Retrospective Studies | 2021 |
Incidence of postoperative endophthalmitis with and without use of intracameral moxifloxacin.
Topics: Anterior Chamber; Anti-Bacterial Agents; Cataract Extraction; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Incidence; Moxifloxacin; Postoperative Complications | 2021 |
Recurrent conjunctivitis secondary to Gram-positive bacillus, Bacillus thuringiensis.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Bacillus thuringiensis; Conjunctivitis, Bacterial; Dexamethasone; Drug Therapy, Combination; Eye Infections, Bacterial; Glucocorticoids; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Recurrence; Tobramycin | 2018 |
Endophthalmitis prophylaxis by intracameral antibiotics: In vitro model comparing vancomycin, cefuroxime, and moxifloxacin.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Humans; Lens Implantation, Intraocular; Lenses, Intraocular; Moxifloxacin; Postoperative Complications; Vancomycin | 2017 |
Standard preoperative topical antibiotics do not additionally benefit in postcataract endophthalmitis prophylaxis.
Topics: Anaphylaxis; Anti-Bacterial Agents; Endophthalmitis; Eye Infections, Bacterial; Humans; Moxifloxacin | 2017 |
Re: Haripriya et al.: Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries (Ophthalmology. 2017;124:768-775).
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Postoperative Complications | 2017 |
Re: Haripriya et al.: Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: an analysis of 600 000 surgeries (Ophthalmology. 2017;124:768-775).
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Postoperative Complications | 2017 |
Systemic Moxifloxacin in Streptococcus viridans Endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Injections, Intraventricular; Moxifloxacin; Rabbits; Streptococcal Infections; Treatment Outcome; Viridans Streptococci; Vitreous Body | 2019 |
Blurry Vision and Eye Pain After Pterygium Surgery.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Eye Infections, Bacterial; Eye Pain; Female; Glucocorticoids; Humans; Indomethacin; Intraocular Pressure; Levofloxacin; Moxifloxacin; Ophthalmologic Surgical Procedures; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Pterygium; Scleritis; Vision Disorders; Visual Acuity | 2018 |
Postsurgical Cataract Prophylaxis With Intravitreal "Triamcinolone-Moxifloxacin" May Not Be Optimal For Preventing Endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Intravitreal Injections; Male; Moxifloxacin; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Triamcinolone | 2018 |
Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: Cost-effectiveness analysis.
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Cost-Benefit Analysis; Endophthalmitis; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Postoperative Complications | 2018 |
Acute-onset postoperative endophthalmitis after cataract surgery and transzonular intravitreal triamcinolone-moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Combinations; Endophthalmitis; Eye Infections, Bacterial; Female; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Male; Moxifloxacin; Phacoemulsification; Retrospective Studies; Surgical Wound Infection; Triamcinolone | 2018 |
Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections.
Topics: Animals; Anti-Bacterial Agents; Cornea; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Keratitis; Mice; Mice, Inbred BALB C; Moxifloxacin; Ophthalmic Solutions; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Trimethoprim | 2019 |
Endophthalmitis after dropless (Tri-Moxi injection) cataract surgery.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Cataract Extraction; Drug Combinations; Drug Implants; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Glucocorticoids; Humans; Intravitreal Injections; Male; Moxifloxacin; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin, Dexamethasone Drug Combination; Triamcinolone; Vancomycin; Vitrectomy | 2020 |
Rapid onset of orbital cellulitis after uncomplicated strabismus surgery.
Topics: Administration, Ophthalmic; Ampicillin; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Esotropia; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Oculomotor Muscles; Ophthalmic Solutions; Orbital Cellulitis; Postoperative Complications; Streptococcal Infections; Streptococcus pyogenes; Sulbactam; Tomography, X-Ray Computed; Vancomycin | 2019 |
Management of Nocardia Interface Keratitis After Descemet Membrane Endothelial Keratoplasty.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Atropine; Ciprofloxacin; Combined Modality Therapy; Descemet Stripping Endothelial Keratoplasty; Drug Therapy, Combination; Eye Infections, Bacterial; Humans; Keratitis; Male; Moxifloxacin; Nocardia asteroides; Nocardia Infections; Ophthalmic Solutions; Reoperation; Retrospective Studies; Visual Acuity | 2019 |
Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries.
Topics: Aged; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; India; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; Phacoemulsification; Posterior Capsular Rupture, Ocular; Postoperative Complications; Registries; Retrospective Studies | 2019 |
Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Toxins; Bacterial Typing Techniques; Corneal Ulcer; DNA, Bacterial; Exotoxins; Eye Infections, Bacterial; Fluoroquinolones; Genotype; Glucocorticoids; Humans; L-Lactate Dehydrogenase; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Virulence; Visual Acuity | 2013 |
The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Conjunctiva; Equipment Contamination; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Injections, Intraocular; Moxifloxacin; Needles; Quinolines; Time Factors | 2013 |
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2013 |
Combination effect of antibiotics against bacteria isolated from keratitis using fractional inhibitory concentration index.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Cefmenoxime; Corneal Ulcer; Drug Combinations; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas; Quinolines; Staphylococcus; Streptococcus; Tobramycin | 2013 |
Infection following photorefractive keratectomy.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Contact Lenses; Equipment Contamination; Eye Infections, Bacterial; Fluorometholone; Fluoroquinolones; Glucocorticoids; Humans; Microbial Sensitivity Tests; Moxifloxacin; Myopia; Photorefractive Keratectomy; Postoperative Complications; Prospective Studies; Quinolines | 2013 |
Molteno implant functioning as a culture plate.
Topics: Administration, Ophthalmic; Adult; Anti-Bacterial Agents; Aza Compounds; Device Removal; Eye Infections, Bacterial; Fluoroquinolones; Glaucoma; Humans; Male; Molteno Implants; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Prosthesis-Related Infections; Quinolines; Reoperation; Treatment Outcome | 2013 |
Antibiotic choice for the prophylaxis of post-cataract extraction endophthalmitis.
Topics: Aged; Aged, 80 and over; Alberta; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Case-Control Studies; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Hospitals, Private; Hospitals, Public; Humans; Incidence; Male; Moxifloxacin; Postoperative Complications; Prospective Studies; Quinolines; Vancomycin | 2014 |
Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Drug Delivery Systems; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Moxifloxacin; Ophthalmic Solutions; Posterior Capsular Rupture, Ocular; Rabbits; Vitreous Body | 2014 |
Safety of besifloxacin ophthalmic suspension 0.6% in cataract and LASIK surgery patients.
Topics: Adult; Aged; Antibiotic Prophylaxis; Azepines; Epidemiological Monitoring; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Prospective Studies; Suspensions; Topoisomerase II Inhibitors; Treatment Outcome; Visual Acuity | 2014 |
Resistant Microbial Keratitis in South Nile Delta, Egypt: Influence of Regional Risk Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Child; Child, Preschool; Climate; Corneal Ulcer; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Resistance, Fungal; Drug Therapy, Combination; Egypt; Eye Infections, Bacterial; Eye Infections, Fungal; Female; Fluoroquinolones; Fungi; Geography; Humans; Incidence; Infant; Infant, Newborn; Ketoconazole; Male; Middle Aged; Moxifloxacin; Natamycin; Prospective Studies; Risk Factors; Social Class | 2016 |
Achromobacter buckle infection diagnosed by a 16S rDNA clone library analysis: a case report.
Topics: Achromobacter; Anti-Bacterial Agents; Betamethasone; Cefdinir; Cephalosporins; Device Removal; DNA, Bacterial; DNA, Ribosomal; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Glucocorticoids; Gram-Negative Bacterial Infections; Humans; Middle Aged; Moxifloxacin; Polymerase Chain Reaction; Prosthesis-Related Infections; Retinal Detachment; RNA, Ribosomal, 16S; Scleral Buckling | 2014 |
Release of Ciprofloxacin and Moxifloxacin From Daily Disposable Contact Lenses From an In Vitro Eye Model.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Contact Lenses, Hydrophilic; Disposable Equipment; Drug Delivery Systems; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin | 2015 |
Incidence of corneal infections after laser in situ keratomileusis and surface ablation when moxifloxacin and tobramycin are used as postoperative treatment.
Topics: Administration, Topical; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Incidence; Keratomileusis, Laser In Situ; Lasers, Excimer; Male; Middle Aged; Moxifloxacin; Myopia; Ophthalmic Solutions; Postoperative Complications; Retrospective Studies; Risk Factors; Tobramycin; Visual Acuity; Young Adult | 2015 |
Microbiologic, Pharmacokinetic, and Clinical Effects of Corneal Collagen Cross-Linking on Experimentally Induced Pseudomonas Keratitis in Rabbits.
Topics: Animals; Anti-Bacterial Agents; Biological Availability; Collagen; Colony Count, Microbial; Cornea; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Photosensitizing Agents; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Riboflavin; Tissue Distribution | 2015 |
Study of the Acute Effects of Povidone-Iodine on Conjunctival Bacterial Flora.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Bacteria; Cadaver; Conjunctiva; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Moxifloxacin; Needles; Povidone-Iodine | 2015 |
Efficacy of Intracameral Moxifloxacin Endophthalmitis Prophylaxis at Aravind Eye Hospital.
Topics: Aged; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Charities; Drug Costs; Electronic Health Records; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Health Care Costs; Hospitals, Private; Hospitals, Public; Hospitals, Special; Humans; India; Male; Middle Aged; Moxifloxacin; Ophthalmology; Postoperative Complications; Registries; Retrospective Studies | 2016 |
Potency and Sterility of Fortified Tobramycin, Fortified Vancomycin, and Moxifloxacin at 4, 24, and 35°C for 14 Days.
Topics: Anti-Bacterial Agents; Drug Stability; Drug Storage; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Humans; Infertility; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Temperature; Time Factors; Tobramycin; Vancomycin | 2016 |
Dropless Cataract Surgery: What Are the Potential Downsides?
Topics: Anti-Infective Agents, Local; Antibiotic Prophylaxis; Drug Compounding; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Glucocorticoids; Humans; Lens Implantation, Intraocular; Moxifloxacin; Ocular Hypertension; Ophthalmic Solutions; Phacoemulsification; Risk Factors; Triamcinolone; Vancomycin | 2016 |
Phase-transition W/O Microemulsions for Ocular Delivery: Evaluation of Antibacterial Activity in the Treatment of Bacterial Keratitis.
Topics: Animals; Anti-Bacterial Agents; Corneal Ulcer; Drug Delivery Systems; Emulsions; Escherichia coli; Eye Infections, Bacterial; Fluoroquinolones; Hexoses; Microscopy, Electron, Transmission; Moxifloxacin; Myristates; Oils; Particle Size; Phase Transition; Polysorbates; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Water | 2017 |
Severe Ocular Bacterial Infections: A Retrospective Study Over 13 Years.
Topics: Anti-Bacterial Agents; Conjunctiva; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus | 2017 |
Re: Haripriya et al.: Efficacy of intracameral moxifloxacin endophthalmitis prophylaxis at Aravind Eye Hospital (Ophthalmology 2016;123:302-308).
Topics: Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Postoperative Complications | 2016 |
Endophthalmitis Reduction with Intracameral Moxifloxacin Prophylaxis: Analysis of 600 000 Surgeries.
Topics: Aged; Anterior Chamber; Anti-Bacterial Agents; Antibiotic Prophylaxis; Cataract Extraction; Electronic Health Records; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; India; Lens Implantation, Intraocular; Male; Microsurgery; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Posterior Capsular Rupture, Ocular; Postoperative Complications; Registries; Retrospective Studies | 2017 |
Moxifloxacin for bacterial keratitis.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Cefazolin; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Tobramycin; Treatment Outcome | 2008 |
Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Injections; Lens Implantation, Intraocular; Macula Lutea; Male; Middle Aged; Moxifloxacin; Postoperative Complications; Prospective Studies; Quinolines; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome | 2008 |
Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application.
Topics: Administration, Topical; Aged; Aza Compounds; Conjunctivitis, Bacterial; Drug Administration Schedule; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Prospective Studies; Quinolines; Time Factors | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
Association between moxifloxacin ophthalmic solution and fungal infection in patients with corneal ulcers and microbial keratitis.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Drug Contamination; Eye Infections, Bacterial; Eye Infections, Fungal; Female; Fluoroquinolones; Humans; Keratitis; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines | 2009 |
Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Colony Count, Microbial; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Keratitis; Moxifloxacin; Ophthalmic Solutions; Postoperative Complications; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus; Staphylococcus epidermidis; Streptococcus pneumoniae; Time Factors | 2009 |
Late-onset laser in situ keratomileusis-related corneal ulcer--a case series.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Male; Middle Aged; Moxifloxacin; Quinolines; Retrospective Studies; Staphylococcal Infections; Streptococcal Infections; Surgical Flaps; Time Factors | 2009 |
Gatifloxacin, moxifloxacin, and balofloxacin resistance due to mutations in the gyrA and parC genes of Staphylococcus epidermidis strains isolated from patients with endophthalmitis, corneal ulcers and conjunctivitis.
Topics: Anti-Infective Agents; Aza Compounds; Conjunctivitis; Corneal Ulcer; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcus epidermidis | 2009 |
Aqueous humor penetration of fourth-generation fluoroquinolone ophthalmic solutions given by multiple administration in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Cataract Extraction; Drug Administration Schedule; Eye; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Models, Animal; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Surgical Wound Infection | 2009 |
Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2009 |
Comparison of antifungal efficacies of moxifloxacin, liposomal amphotericin B, and combination treatment in experimental Candida albicans endophthalmitis in rabbits.
Topics: Amphotericin B; Animals; Antifungal Agents; Aza Compounds; Candida albicans; Candidiasis; Colony Count, Microbial; Disease Models, Animal; Drug Resistance, Fungal; Drug Therapy, Combination; Endophthalmitis; Eye Diseases; Eye Infections, Bacterial; Eye Infections, Fungal; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Vitreous Body | 2010 |
Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Cornea; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Treatment Outcome | 2010 |
Oral moxifloxacin and topical amikacin for Mycobacterium abscessus keratitis after laser in situ keratomileusis.
Topics: Administration, Oral; Administration, Topical; Amikacin; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Postoperative Complications; Quinolines; Young Adult | 2010 |
Comparing the effectiveness of moxifloxacin and povidone-iodine with povidone-iodine alone.
Topics: Administration, Topical; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Ophthalmologic Surgical Procedures; Povidone-Iodine; Quinolines; Surgical Wound Infection; Treatment Outcome | 2010 |
Spontaneous subconjunctival abscess because of Haemophilus influenzae.
Topics: Abscess; Adult; Anti-Infective Agents; Aza Compounds; Conjunctival Diseases; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Moxifloxacin; Quinolines; Tobramycin; Tomography, X-Ray Computed; Vancomycin | 2010 |
Effects of photodynamic therapy on rapidly growing nontuberculous mycobacteria keratitis.
Topics: Amikacin; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Methylene Blue; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Photochemotherapy; Quinolines; Rabbits | 2011 |
Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Azepines; Colony Count, Microbial; Corneal Ulcer; Disease Models, Animal; Disease Susceptibility; DNA, Bacterial; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Sequence Analysis, DNA | 2011 |
Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.
Topics: Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Azepines; Biological Availability; Colony-Forming Units Assay; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Methicillin Resistance; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome | 2010 |
Prophylactic effect of intravenous moxifloxacin in a rabbit model of Staphylococcus epidermidis endophthalmitis.
Topics: Animals; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections, Intravenous; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin | 2011 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2011 |
Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Aza Compounds; Child; Child, Preschool; Clarithromycin; Combined Modality Therapy; Corneal Ulcer; Eye Infections, Bacterial; Female; Florida; Fluoroquinolones; Humans; Incidence; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Ophthalmologic Surgical Procedures; Quinolines; Retrospective Studies; Risk Factors; Surgical Wound Infection; Young Adult | 2012 |
[The effectiveness of intraocular delivery of 5-fluoroquinolones for prophylaxis of intraocular infection].
Topics: Anti-Bacterial Agents; Aza Compounds; Eye Infections, Bacterial; Eye Injuries; Female; Fluoroquinolones; Gatifloxacin; Humans; Injections, Intraocular; Levofloxacin; Male; Military Medicine; Moxifloxacin; Ofloxacin; Quinolines; Warfare | 2011 |
A case of Stenotrophomonas maltophilia keratitis effectively treated with moxifloxacin.
Topics: Aged; Anti-Infective Agents; Aza Compounds; Cornea; Diagnosis, Differential; Eye Infections, Bacterial; Fluoroquinolones; Follow-Up Studies; Gram-Negative Bacterial Infections; Humans; Keratitis; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Stenotrophomonas maltophilia; Visual Acuity | 2011 |
Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection.
Topics: Administration, Topical; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteria; Case-Control Studies; Conjunctiva; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Intravitreal Injections; Macular Degeneration; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Polymyxin B; Quinolines; Trimethoprim | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Bacteria; Cataract Extraction; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Postoperative Complications; Quinolines; Retrospective Studies; Vancomycin; Visual Acuity; Vitreous Body | 2012 |
Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% povidone-iodine.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Corneal Diseases; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Male; Molecular Diagnostic Techniques; Moxifloxacin; Povidone-Iodine; Prospective Studies; Prostheses and Implants; Quinolines; Staphylococcus aureus | 2013 |
Infectious nontuberculous serpiginous choroiditis.
Topics: Adult; Anti-Infective Agents; Antibodies, Bacterial; Aza Compounds; Bartonella henselae; Cat-Scratch Disease; Choroiditis; Ciprofloxacin; Eye Infections, Bacterial; Fluorescein Angiography; Fluoroquinolones; Francisella tularensis; Humans; Immunoglobulin G; Male; Middle Aged; Moxifloxacin; Quinolines; Tularemia; Vision Disorders; Visual Acuity | 2012 |
Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azepines; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Lens Implantation, Intraocular; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Retrospective Studies | 2012 |
Bilateral corneal ulceration in keratoconus.
Topics: Aza Compounds; Collagen; Corneal Stroma; Corneal Ulcer; Cross-Linking Reagents; Doxycycline; Drug Therapy, Combination; Electrocoagulation; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratoconus; Male; Middle Aged; Moxifloxacin; Photosensitizing Agents; Postoperative Complications; Prostheses and Implants; Prosthesis Implantation; Quinolines; Staphylococcal Infections; Vancomycin | 2012 |
Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department.
Topics: Aged; Anterior Eye Segment; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; California; Cefuroxime; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Incidence; Lens Implantation, Intraocular; Moxifloxacin; Phacoemulsification; Postoperative Complications; Quinolines; Vancomycin | 2013 |
In vitro comparison of combination and monotherapy for the empiric and optimal coverage of bacterial keratitis based on incidence of infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Cefazolin; Cefuroxime; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Tobramycin | 2013 |
Moxifloxacin resistance: intrinsic to antibiotic or related to mutation?
Topics: Anti-Bacterial Agents; Aza Compounds; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Retrospective Studies | 2012 |
Cotrimoxazole-resistant Nocardia sclerokeratitis: effective therapy with fourth-generation fluoroquinolones.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Nocardia; Nocardia Infections; Quinolines; Scleritis; Trimethoprim, Sulfamethoxazole Drug Combination | 2012 |
Improvement in corneal scarring following bacterial keratitis.
Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Pneumococcal Infections; Prednisolone; Pseudomonas Infections; Quinolines; Vision Disorders; Visual Acuity | 2013 |
Moxifloxacin as postoperative prophylaxis for Enterococcus faecalis-induced endophthalmitis after cataract surgery in aphakic rabbits.
Topics: Administration, Ophthalmic; Animals; Anti-Bacterial Agents; Aphakia, Postcataract; Aza Compounds; Disease Models, Animal; Electroretinography; Endophthalmitis; Enterococcus faecalis; Eye Infections, Bacterial; Fluoroquinolones; Gram-Positive Bacterial Infections; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Phacoemulsification; Quinolines; Rabbits; Time Factors | 2013 |
Ocular pharmacokinetics, safety and efficacy of intracameral moxifloxacin 0.5% solution in a rabbit model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Endophthalmitis; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Injections, Intraocular; Microscopy, Electron, Transmission; Moxifloxacin; Phacoemulsification; Quinolines; Rabbits; Staphylococcal Infections; Streptococcal Infections; Vitreous Body | 2013 |
Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model.
Topics: Administration, Topical; Animals; Anterior Chamber; Aza Compounds; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Moxifloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols.
Topics: Animals; Anti-Infective Agents, Local; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Microscopy, Electron, Scanning; Moxifloxacin; No-Observed-Adverse-Effect Level; Quinolines; Rabbits | 2005 |
Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model.
Topics: Adrenal Cortex Hormones; Animals; Anti-Infective Agents; Aza Compounds; Dexamethasone; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Inflammation; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus epidermidis; Stem Cells; Time Factors; Vitreous Body | 2005 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Methicillin Resistance; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Topics: Animals; Anterior Chamber; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections; Moxifloxacin; No-Observed-Adverse-Effect Level; Ophthalmic Solutions; Quinolines; Rabbits; Safety; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Vancomycin; Vitreous Body | 2005 |
Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery.
Topics: Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Postoperative Complications; Quinolines; Surgical Flaps; Tobramycin | 2005 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Intracameral Vigamox (moxifloxacin 0.5%) is not effective in preventing endophthalmitis in a rabbit model.
Topics: Animals; Anterior Chamber; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Injections; Moxifloxacin; No-Observed-Adverse-Effect Level; Quinolines; Rabbits; Staphylococcal Infections | 2006 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.
Topics: Adult; Aza Compounds; Bacteria; Cornea; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Keratoplasty, Penetrating; Lasers, Excimer; Microbial Sensitivity Tests; Moxifloxacin; Myopia; Photorefractive Keratectomy; Postoperative Complications; Pseudomonas Infections; Quinolines; Staphylococcal Infections | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
Selecting between gatifloxacin and moxifloxacin drops in ambulatory ophthalmic surgery.
Topics: Ambulatory Surgical Procedures; Anti-Bacterial Agents; Aza Compounds; Drug Costs; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmologic Surgical Procedures; Postoperative Complications; Quinolines | 2006 |
Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Cataract Extraction; Drug Resistance, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Postoperative Complications; Quinolines; Retrospective Studies | 2006 |
Effect of the fourth-generation fluoroquinolones on corneal reepithelialization after penetrating keratoplasty.
Topics: Anti-Bacterial Agents; Aza Compounds; Epithelium, Corneal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratoplasty, Penetrating; Moxifloxacin; Postoperative Complications; Quinolines; Wound Healing | 2006 |
Bilateral simultaneous Achromobacter xylosoxidans keratitis following penetrating keratoplasty.
Topics: Achromobacter denitrificans; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Keratoplasty, Penetrating; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Piperacillin; Quinolines | 2006 |
Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Quinolines; Retrospective Studies; Vitreous Body | 2007 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Coagulase; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Microbiological Techniques; Moxifloxacin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Vancomycin; Virginiamycin | 2007 |
Fourth-generation fluoroquinolone-resistant bacterial keratitis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2007 |
The increasing problem of antibiotic resistance.
Topics: Anti-Infective Agents; Aza Compounds; Corneal Ulcer; Drug Resistance, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines | 2007 |
Fourth-generation fluoroquinolone-resistant mycobacterial keratitis after laser in situ keratomileusis.
Topics: Adult; Amikacin; Anti-Infective Agents; Aza Compounds; Clarithromycin; Corneal Ulcer; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Keratomileusis, Laser In Situ; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Quinolines | 2007 |
Late bacterial keratitis after intracorneal ring segments (Ferrara ring) insertion for keratoconus.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Corneal Stroma; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Keratoconus; Microbial Sensitivity Tests; Moxifloxacin; Postoperative Complications; Prostheses and Implants; Prosthesis Implantation; Quinolines; Staphylococcal Infections; Vancomycin | 2007 |
Fluoroquinolone therapy in a rabbit model of post-LASIK methicillin-resistant Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Keratomileusis, Laser In Situ; Methicillin Resistance; Moxifloxacin; Postoperative Complications; Quinolines; Rabbits; Specific Pathogen-Free Organisms; Staphylococcal Infections; Staphylococcus aureus; Surgical Flaps | 2008 |
Endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Bacteria; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Phacoemulsification; Postoperative Complications; Quinolines; Vitreous Body | 2008 |
Early bacterial keratitis after presbyopic LASIK.
Topics: Administration, Oral; Administration, Topical; Anti-Infective Agents, Local; Aza Compounds; Bacitracin; Cornea; Corneal Ulcer; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Keratomileusis, Laser In Situ; Microscopy, Confocal; Middle Aged; Moxifloxacin; Pain, Postoperative; Presbyopia; Propionibacterium acnes; Quinolines; Visual Acuity | 2008 |
Phlyctenular keratoconjunctivitis in a patient with Staphylococcal blepharitis and ocular rosacea.
Topics: Administration, Oral; Administration, Topical; Adult; Aza Compounds; Blepharitis; Cyclosporine; Doxycycline; Drug Therapy, Combination; Eye Infections, Bacterial; Fluoroquinolones; Humans; Keratoconjunctivitis; Male; Moxifloxacin; Ophthalmic Solutions; Prednisolone; Quinolines; Rosacea; Staphylococcal Infections | 2008 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |